HARBIN, China, May 26 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company in the People's Republic of China ("PRC"), today announced that it recently obtained production approval from the State Food and Drug Administration (SFDA) in China for two of its newly developed drugs.
Acyclovir gel is used to treat the skin infection due to varicella-zoster virus and the herpes simplex virus. Shuanghuanglian suppositories helps relieve cold and flu symptoms such as fever, cough and sore throat pain. It can also be used to treat upper respiratory infections and pneumonia. Both of the products are for common diseases, and should benefit as a result of the rapidly expanded rural health market, especially after China's recent reform of the insurance system. They will be introduced to the market in the third quarter of 2009.
China Sky One Medical started R&D of the two drugs in 2003 and submitted the applications for SFDA approval in early 2007. The document numbers for the drugs are H20093399 and Z20093134. In all, China Sky One Medical has received production approval for 25 products since January 2008, including six new products in 2009. Currently, the Company has over 20 products in the application process under SFDA review.
Recently the Company also received the approval from SFDA for Diclofenac Sodium suppositories to enter the clinical trial, with the document number 2009L02108. This drug is used to treat rheumatoid arthritis and to relieve pain after operations and fever.
"We are excited about our new drug approvals, which are a testament to our
outstanding R&D capability and our understanding of the pharmaceutical market
in China," said Mr. Yan-Qing Liu, Chairman and
|SOURCE China Sky One Medical, Inc.|
Copyright©2009 PR Newswire.
All rights reserved